Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,054 matching trials from the live ClinicalTrials.gov search.
Conditions
Malignant Melanoma
Interventions
Atezolizumab, Cobimetinib
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Detroit, Michigan + 3 more
Conditions
Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Melanoma
Interventions
Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Melanoma Stage III, Melanoma
Interventions
nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
Interventions
dabrafenib, trametinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Pigmented Skin Lesions With MelaFind(R) System

NCT00434057
Conditions
Melanoma
Interventions
MelaFind(R)
Device
Lead sponsor
MELA Sciences, Inc.
Industry
Eligibility
Not listed
Enrollment
1,383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Plantation, Florida • Tallahassee, Florida
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Conditions
LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1, Solid Tumor, Pediatric Tumors, Neurocutaneous Melanocytosis, Congenital Melanocytic Nevus, Arachnoid Cysts, Astrocytoma, Ependymoma, Melanoma
Interventions
Mirdametinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

NCT02404441
Conditions
Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer, Other Solid Tumors
Interventions
PDR001
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 3 more
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Melanoma (Skin)
Interventions
aldesleukin, gp100 antigen, incomplete Freund's adjuvant, sargramostim, tetanus peptide melanoma vaccine, tyrosinase peptide
Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Melanoma
Interventions
dacarbazine plus Genasense, dacarbazine plus placebo
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more
Completed Not applicable Interventional

Isotretinoin in Preventing Skin Cancer

NCT00025012
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
isotretinoin
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Conditions
Melanoma
Interventions
Ipilimumab, Vemurafenib
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Beverly Hills, California • Jacksonville, Florida • Orlando, Florida + 8 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

NCT05488483
Conditions
Breast Cancer, Melanoma
Interventions
Multispectral Optoacoustic Tomography Imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Montvale, New Jersey • Commack, New York • New York, New York
Conditions
Dysplastic Nevi
Interventions
Saucerization biopsy
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
SX-682, Pembrolizumab
Drug · Biological
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Conditions
Melanoma, Brain Metastases
Interventions
Craniotomy scheduled, Collection for non-craniotomy
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Conditions
Non-Melanoma Skin Cancers
Interventions
SM-020 1% Gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Melanoma
Interventions
Entinostat, Pembrolizumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Biospecimen Collection, Cholecalciferol, Computed Tomography, Desloratadine, Immunotherapy, Infusion Procedure, Magnesium Sulfate, Magnetic Resonance Imaging, Propranolol
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Nonmelanoma Skin Cancer
Interventions
Electronic Brachytherapy
Procedure
Lead sponsor
Xoft, Inc.
Industry
Eligibility
41 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Los Gatos, California • San Diego, California • Las Vegas, Nevada